

# P 22077

Catalog No: tcsc1860



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1247819-59-5

**Formula:**

$C_{12}H_7F_2NO_3S_2$

**Pathway:**

Cell Cycle/DNA Damage

**Target:**

Deubiquitinase

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 53.3$  mg/mL (169.03 mM)

**Observed Molecular Weight:**

315.32


## Product Description

P 22077 is a cell-permeable **ubiquitin-specific protease 7 (USP7)** inhibitor with an **EC<sub>50</sub>** of 8.01  $\mu$ M. It also inhibits USP47 with an **EC<sub>50</sub>** of 8.74  $\mu$ M.

IC50 & Target: EC50: 8.01  $\mu$ M (USP7), 8.74  $\mu$ M (USP47)<sup>[1]</sup>

**In Vitro:** P 22077 is an inhibitor of USP7 and DUB USP47, with EC<sub>50</sub>s of 8.01  $\mu$ M and 8.74  $\mu$ M, respectively. P 22077 (15-45  $\mu$ M) inhibits a much smaller subset of DUBs. P 22077 (25  $\mu$ M) causes DUBs inhibition in HEK293T cells<sup>[1]</sup>. P 22077 (0-20  $\mu$ M) greatly reduces the cell viability of Neuroblastoma (NB) cells including IMR-32, NGP, CHLA-255, and SH-SY5Y cells but without NB-19 and SK-N-AS cells. P 22077 (10  $\mu$ M) increases p53 activity and induces apoptosis in p53 wild-type and HDM2-expressing NB cells. P 22077 (5  $\mu$ M) enhances the cytotoxic effect of Dox and VP-16 on NB cells, and enhances Dox- and VP-16-induced p53-mediated apoptosis<sup>[2]</sup>.

**In Vivo:** P 22077 (15 mg/kg, i.p. 21 days) shows potent antitumor activities in an xenograft mouse model bearing IMR-32-derived tumors; P 22077 also exhibits antitumor effects after treatment at 10 mg/kg for 14 days in mice bearing SH-SY5Y-derived tumors, and at 20 mg/kg for 12 days in mice bearing NGP-derived tumors<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!